These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Blauwendraat C; Reed X; Krohn L; Heilbron K; Bandres-Ciga S; Tan M; Gibbs JR; Hernandez DG; Kumaran R; Langston R; Bonet-Ponce L; Alcalay RN; Hassin-Baer S; Greenbaum L; Iwaki H; Leonard HL; Grenn FP; Ruskey JA; Sabir M; Ahmed S; Makarious MB; Pihlstrøm L; Toft M; van Hilten JJ; Marinus J; Schulte C; Brockmann K; Sharma M; Siitonen A; Majamaa K; Eerola-Rautio J; Tienari PJ; ; Pantelyat A; Hillis AE; Dawson TM; Rosenthal LS; Albert MS; Resnick SM; Ferrucci L; Morris CM; Pletnikova O; Troncoso J; Grosset D; Lesage S; Corvol JC; Brice A; Noyce AJ; Masliah E; Wood N; Hardy J; Shulman LM; Jankovic J; Shulman JM; Heutink P; Gasser T; Cannon P; Scholz SW; Morris H; Cookson MR; Nalls MA; Gan-Or Z; Singleton AB Brain; 2020 Jan; 143(1):234-248. PubMed ID: 31755958 [TBL] [Abstract][Full Text] [Related]
14. Mutations in the glucocerebrosidase gene are common in patients with Parkinson's disease from Eastern Canada. Han F; Grimes DA; Li F; Wang T; Yu Z; Song N; Wu S; Racacho L; Bulman DE Int J Neurosci; 2016; 126(5):415-21. PubMed ID: 26000814 [TBL] [Abstract][Full Text] [Related]
16. Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort. Crosiers D; Verstraeten A; Wauters E; Engelborghs S; Peeters K; Mattheijssens M; De Deyn PP; Theuns J; Van Broeckhoven C; Cras P Neurosci Lett; 2016 Aug; 629():160-164. PubMed ID: 27397011 [TBL] [Abstract][Full Text] [Related]
17. Visual short-term memory deficits associated with GBA mutation and Parkinson's disease. Zokaei N; McNeill A; Proukakis C; Beavan M; Jarman P; Korlipara P; Hughes D; Mehta A; Hu MT; Schapira AH; Husain M Brain; 2014 Aug; 137(Pt 8):2303-11. PubMed ID: 24919969 [TBL] [Abstract][Full Text] [Related]
18. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. Mielke MM; Maetzler W; Haughey NJ; Bandaru VV; Savica R; Deuschle C; Gasser T; Hauser AK; Gräber-Sultan S; Schleicher E; Berg D; Liepelt-Scarfone I PLoS One; 2013; 8(9):e73094. PubMed ID: 24058461 [TBL] [Abstract][Full Text] [Related]
19. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease. da Silva CP; de M Abreu G; Cabello Acero PH; Campos M; Pereira JS; de A Ramos SR; Nascimento CM; Voigt DD; Rosso AL; Araujo Leite MA; Vasconcellos LFR; Nicaretta DH; Della Coletta MV; da Silva DJ; Gonçalves AP; Dos Santos JM; Calassara V; Valença DCT; de M Martins CJ; Santos-Rebouças CB; Pimentel MMG J Neurol Sci; 2017 Oct; 381():160-164. PubMed ID: 28991672 [TBL] [Abstract][Full Text] [Related]
20. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives. Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]